Introduction {#s1}
============

Most animal cells express inositol 1,4,5-trisphosphate receptors (IP~3~R), which fulfil an essential role in linking the many cell-surface receptors that stimulate IP~3~ formation to release of Ca^2+^ from the endoplasmic reticulum [@pone.0054877-Taylor1]. Vertebrates have genes for three IP~3~R subunits, while invertebrates have only a single IP~3~R gene. All functional IP~3~R are tetrameric assemblies of these subunits. The similar primary sequences of the IP~3~R subunits suggest that all IP~3~R are likely to share similar structures, although we presently have only a limited understanding of the structure of the entire IP~3~R [@pone.0054877-Taylor1], [@pone.0054877-Ludtke1]. Each subunit has an N-terminal region to which IP~3~ binds. This region comprises the N-terminal suppressor domain (SD, residues 1--223) and the IP~3~-binding core (IBC, residues 224--604 in IP~3~R1, [Figure 1A](#pone-0054877-g001){ref-type="fig"}), which is alone sufficient to bind IP~3~ with appropriate selectivity [@pone.0054877-Bosanac1]. The SD both modulates the affinity of the IBC for agonists and provides an essential link between IP~3~ binding and opening of the pore [@pone.0054877-Rossi1], [@pone.0054877-Chan1], [@pone.0054877-Yamazaki1], [@pone.0054877-Seo1]. A large cytoplasmic region separates the N-terminal from the six transmembrane domains. The last pair of these, together with the intervening luminal loop, form the Ca^2+^-permeable pore [@pone.0054877-RamosFranco1] ([Figure 1A](#pone-0054877-g001){ref-type="fig"}). Each subunit terminates in a short C-terminal tail, which has also been implicated in the regulation of gating [@pone.0054877-Uchida1]. The diversity provided by three genes is further increased by multiple splice variants of at least two of the three IP~3~R subtypes (IP~3~R1 and IP~3~R2), by formation of homo- or hetero-tetrameric assemblies of IP~3~R subunits, by association with an enormous diversity of modulatory proteins and by post-translational modifications [@pone.0054877-Foskett1]. At present, we have only a limited understanding of the functional significance of this complexity for IP~3~-evoked Ca^2+^ signals in native tissues.

![Structure of the N-terminal of the IP~3~ receptor and structures of the ligands used.\
(A) Key regions of a single IP~3~R subunit (numbering for rat IP~3~R1) are shown highlighting N-terminal domains and the six C-terminal transmembrane domains (TMD) that form the pore. A high-resolution structure of the N-terminal (NT, residues 1--604) with (1,4,5)IP~3~ bound is shown (Protein Data Bank, 3UJO). The NT comprises the suppressor domain (SD) and IP~3~-binding core (IBC). The essential 4- and 5-phosphate groups of (1,4,5)IP~3~ interact with residues in the β-domain and α-domain of the IBC, respectively. (B) Structures of the ligands used.](pone.0054877.g001){#pone-0054877-g001}

The broadly similar structures of the three IP~3~R subunits are matched by many shared functional properties, most notably co-regulation of all IP~3~R by IP~3~ and Ca^2+^ [@pone.0054877-Foskett1], [@pone.0054877-Marchant1]. Nevertheless, there are differences in the patterns of expression of IP~3~R in different tissues [@pone.0054877-Fujino1], [@pone.0054877-YamamotoHino1], in their subcellular distributions [@pone.0054877-Taylor2], [@pone.0054877-Vermassen1], sensitivities to IP~3~ [@pone.0054877-Iwai1], modulation by accessory proteins and additional signals [@pone.0054877-Patterson1], [@pone.0054877-Ando1], [@pone.0054877-Higo1], and in the functional consequences of IP~3~R ablation [@pone.0054877-Futatsugi1], [@pone.0054877-Matsumoto1]. Heterogeneous populations of IP~3~R in most cells make it difficult to establish clearly the characteristics of each IP~3~R subtype and to define their functional roles. A better knowledge of the ligand recognition properties of the three IP~3~R3 subtypes is needed if ligands selective for IP~3~R subtypes are to be developed to help resolve these problems. All known high-affinity agonists of IP~3~R retain structures equivalent to the 4,5-bisphosphate and 6-hydroxyl groups of (1,4,5)IP~3~ ([Figure 1B](#pone-0054877-g001){ref-type="fig"}) [@pone.0054877-Potter1]. The only exception is a low-affinity analogue of adenophostin A (3″-dephospho-adenophostin A) in which interactions between the adenine moiety and IP~3~R appear partially to compensate for loss of a phosphate (equivalent to the 5-phosphate of (1,4,5)IP~3~) within the critical bisphosphate moiety [@pone.0054877-Sureshan1]. Here we use a selection of synthetic analogues of IP~3~ that preserve the key structures of the high-affinity agonists to assess their activity at each IP~3~R subtype.

Materials and Methods {#s2}
=====================

Materials {#s2a}
---------

Thapsigargin was from Alomone Laboratories (Jerusalem, Israel). The structures of the ligands used and their abbreviations are shown in [Figure 1B](#pone-0054877-g001){ref-type="fig"}. (1,4,5)IP~3~ was from Alexis Biochemicals (Nottingham, U.K.). 3-deoxy(1,4,5)IP~3~, (1,3,4)IP~3~ and (1,3,4,5)IP~4~ were from Calbiochem (Nottingham, U.K.). (1,4,6)IP~3~ from both Alexis Biochemicals and synthesized as reported previously [@pone.0054877-Mills1] was used. Malachite green IP~3~ (MG(1,4,5)IP~3~) was synthesized using the methods described by Inoue *et al*. [@pone.0054877-Inoue1]. (4,5)IP~2~ [@pone.0054877-Sureshan2], 2-deoxy(1,4,5)IP~3~ [@pone.0054877-Poinas1] and synthetic (1,3,4,5)IP~4~ [@pone.0054877-Riley1] were synthesized as previously described. All synthesized ligands were purified by ion-exchange chromatography, fully characterized by the usual spectroscopic methods and accurately quantified by total phosphate assay. ^3^H-IP~3~ (185 Bq/mmol) was from PerkinElmer (Bucks, U.K.).

Anti-peptide antisera to peptides conserved in all mammalian IP~3~R subtypes (AbC, residues 62--75 of rat IP~3~R1) or unique to IP~3~R1 (Ab1, residues 2724--2739) or IP~3~R2 (Ab2, residues 2685--2701) were described previously [@pone.0054877-Cardy1]. A monoclonal antibody that recognizes N-terminal residues (22--230) of IP~3~R3 (Ab3) was from BD Transduction Laboratories (Oxford, U.K.). Anti-β-actin antibody was from AbCam (Cambridge, U.K.). Donkey secondary antibodies (anti-rabbit or anti-mouse) conjugated to horseradish peroxidase were from Santa Cruz Biotechnology (Santa Cruz, CA, U.S.A.). Sources of other materials are provided in earlier publications [@pone.0054877-Rossi2], [@pone.0054877-Tovey1].

Cell Culture {#s2b}
------------

DT40 cells lacking genes for all three IP~3~R subtypes (DT40-KO cells) [@pone.0054877-Sugawara1] and the same cells stably expressing rat IP~3~R1 (GenBank accession number GQ233032.1) [@pone.0054877-Pantazaka1], mouse IP~3~R2 (GU980658.1) [@pone.0054877-Tovey1] or rat IP~3~R3 (GQ233031.1) [@pone.0054877-Rahman1] were cultured in RPMI 1640 medium supplemented with 10% foetal bovine serum, 1% heat-inactivated chicken serum, 2 mM glutamine and 50 µM 2-mercaptoethanol at 37°C in 95% air and 5% CO~2~. Cells were passaged every 2 days when they reached a density of ∼1.5×10^6^ cells/mL.

Immunoblotting {#s2c}
--------------

Cells (∼7×10^7^) were centrifuged (650 *g*, 5 min), resuspended in Hepes-buffered saline (HBS), re-centrifuged, and the pellet was solubilized in 1 mL of medium containing 140 mM NaCl, 5 mM NaF, 10 mM Tris, 1 mM Na~4~P~2~O~7~, 0.4 mM Na~3~VO~4~, 1% Triton X-100 and a protease inhibitor tablet (1 tablet/10 mL, Roche Diagnostics, Mannheim, Germany). HBS had the following composition: 135 mM NaCl, 5.9 mM KCl, 1.2 mM MgCl~2~, 1.5 mM CaCl~2~, 11.6 mM Hepes, 11.5 mM glucose, pH 7.3. The solubilized cells were sonicated on ice (Trans Scientific 1420 sonicator, 50--60 Hz, 3×10 s), incubated with gentle rotation for 1 h at 2°C and then centrifuged (6000 *g*, 10 min). A sample of the supernatant (13 µL) was mixed with [dl]{.smallcaps}-dithiothreitol (2 µL, 100 mM) and NuPAGE LDS sample buffer (5 µL, Invitrogen, Paisley, U.K.). After heating (70°C, 10 min), 20-µL samples were loaded onto NuPAGE 3--8% Tris acetate gels for SDS-PAGE using Novex Tris acetate buffer (Invitrogen). Broad range spectrum marker and MagicMark molecular weight markers (Invitrogen) were used to monitor protein migration during SDS-PAGE and for calibration, respectively. After transfer to a PVDF membrane using an iBlot dry-blotting system (Invitrogen), the membrane was blocked by incubation (1 h) with Tris-buffered saline (TBS) containing 5% non-fat dry milk. It was then incubated with primary antiserum (1∶1000 and 1∶10,000 for IP~3~R and β-actin antibodies, respectively) in TBS containing 2.5% w/v BSA for 12 h. TBS had the following composition: 140 mM NaCl, 20 mM Tris, 0.1% v/v Tween, pH 7.6. After incubation with primary antibodies, the blots were washed in TBS (3×5 min), incubated with horseradish peroxidase-conjugated secondary antibodies (1∶1000, donkey anti-rabbit or donkey anti-mouse) for 1 h in TBS supplemented with 2.5% BSA, and washed again (3×5 min). Bands were detected using Supersignal West Pico chemiluminescent substrate (ThermoScientific, Rockford, IL, U.S.A.) and quantified using GeneTools software (Syngene, Frederick, MD, U.S.A.).

Measurement of IP~3~-evoked Ca^2+^ Release {#s2d}
------------------------------------------

A low-affinity Ca^2+^ indicator (Mag fluo-4) trapped within the ER lumen was used to measure IP~3~-evoked Ca^2+^ release from permeabilized DT40 cells stably expressing mammalian IP~3~R [@pone.0054877-Tovey2]. Cells (50 mL, 10^6^ cells/mL) were loaded with Mag fluo-4 AM (20 µM) in HBS supplemented with pluronic F127 (0.02% w/v) for 1 h at 20°C in the dark with gentle shaking. The cells were centrifuged (650 *g*, 5 min), resuspended in Ca^2+^-free cytosol like medium (CLM) and permeabilized by addition of saponin (10 µg/mL, ∼4 min, 37°C). Ca^2+^-free CLM had the following composition: 140 mM KCl, 2 mM NaCl, 1 mM EGTA, 2 mM MgCl~2~, 20 mM Pipes, pH 7. After washing (650 *g*, 2 min), permeabilized cells were resuspended in CLM without Mg^2+^, but supplemented with CaCl~2~ (375 µM) to give a final free \[Ca^2+^\] of ∼220 nM (after addition of 1.5 mM MgATP) and with carbonyl cyanide 4-trifluoromethoxy-phenyl hydrazone (FCCP, 10 µM) to inhibit mitochondrial Ca^2+^ uptake. Cells were distributed (5×10^5^ cells/well) into half area 96-well, black-walled, poly-lysine-coated plates and centrifuged (300 *g*, 2 min). Fluorescence (excitation and emission wavelengths of 485 nm and 520 nm, respectively) was recorded at 1-s intervals using a FlexStation™ 3 fluorescence plate reader (Molecular Devices, Berkshire, U.K.) at 20°C. Addition of MgATP (1.5 mM) allowed Ca^2+^ uptake into the intracellular stores, and after 150 s, IP~3~ (or its analogues) was added together with thapsigargin (1 µM) to prevent further Ca^2+^ uptake. IP~3~-evoked Ca^2+^ release is expressed as a fraction of that released by addition of ionomycin (1 µM) [@pone.0054877-Tovey2].

^3^H-IP~3~ Binding to Native Type 1 IP~3~ Receptors {#s2e}
---------------------------------------------------

Mouse cerebellar membranes (5 mg protein) in a final volume of 500 µL of CLM with a free \[Ca^2+^\] of 220 nM were incubated with ^3^H-IP~3~ (1.5 nM) and appropriate concentrations of competing ligand at 4°C [@pone.0054877-Rossi1]. After 5 min, during which equilibrium was attained, the reactions were terminated by centrifugation (2000 *g*). The supernatant was removed and the pellet was washed (500 µL CLM) and then solubilized (200 µL CLM with 1% v/v Triton-X-100) before determining its radioactivity using Ecoscint A scintillation cocktail (National Diagnostics, Atlanta, GA, USA, 1 mL). Total ^3^H-IP~3~ binding was ∼3000 disintegrations/min (d.p.m.) and non-specific binding was ∼300 d.p.m. (determined by addition of 1 µM IP~3~ or by extrapolation of IP~3~ competition curves to infinite IP~3~ concentration). Results were fitted to Hill equations (GraphPad Prism, version 5, GraphPad Software Inc., CA, U.S.A.) from which half-maximal inhibitory concentration (IC~50~) and thereby K~D~ values were calculated.

Statistical Analysis {#s2f}
--------------------

Concentration-effect relationships were fitted to Hill equations using Graph Pad Prism, from which Hill coefficients (h), the fraction of the intracellular Ca^2+^ stores released by maximally effective concentrations of agonist, and pEC~50~ values were calculated. For clarity, some results are reported as EC~50~ values, but all statistical comparisons used pEC~50~ values. Each experiment included an analysis of the effects of (1,4,5)IP~3~ to allow paired comparisons of pEC~50~ values for IP~3~ and each analogue (ΔpEC~50~). Results are expressed as means ± SEM for n independent experiments, with each experiment performed in triplicate. Statistical comparisons used paired Student's t test or ANOVA followed by Bonferroni test, with *P*\<0.05 is considered significant.

Homology Modelling and Ligand Docking {#s2g}
-------------------------------------

Sequence alignments were performed using MUSCLE (<http://www.ebi.ac.uk/Tools/msa/muscle/>). Structural homology models were built in Modeller 9.10 [@pone.0054877-Eswar1] using templates of crystal structures of the IBC (Protein Data Bank: 1N4K) and SD (Protein Data Bank: 1XZZ). The geometric qualities of the models were evaluated with the Molprobity server [@pone.0054877-Davis1]. Finally, the N-terminal regions of mouse IP~3~R2 and rat IP~3~R3 comprising the modelled SD and IBC structures of each were reconstructed by aligning the individual domains against cognate regions of the NT of rat IP~3~R1 (Protein Data Bank: 3UJ4) [@pone.0054877-Seo1] using UCSF Chimera 1.6.1 [@pone.0054877-Pettersen1].

We used docking of IP~3~ analogues into a rigid IBC and subsequent superposition of the structure onto a model of the entire IP~3~R solely to assess whether full-length IP~3~R was likely to bind the analogues without steric clashes. Docking of IP~3~ analogues was performed using the IBC (Protein Data Bank: 1N4K) [@pone.0054877-Bosanac1] and AutoDock Vina 1.1.2 [@pone.0054877-Trott1]. Prior to docking, bound (1,4,5)IP~3~ and all water molecules (except those within 5 Å of the IP~3~-binding site) were removed. The search space comprised a grid of 20×20×20 points, each separated by 0.375 Å, around the IP~3~-binding site. Ligands (except (1,4,5)IP~3~) were drawn and energy-minimized with MM2 force field using ChemBioOffice 2008 (<http://www.cambridgesoft.com>). Polar hydrogens and the Gasteiger partial atomic charges were then added to the protein and ligands using AutoDockTools (<http://autodock.scripps.edu/resources/adt>), and the prepared structures were used as input files for docking. Only the best pose is considered for each ligand. For MG(1,4,5)IP~3~, the ligand was superposed onto (1,4,5)IP~3~ within the NT monomer (Protein Data Bank: 3UJ0A) and the complex (with (1,4,5)IP~3~-removed) was energy-minimized using MMFF94 Forcefield [@pone.0054877-Merlino1]. PyMol was used to present docked structures (<http://pymol.sourceforge.net/>).

Results {#s3}
=======

Expression of Mammalian IP~3~ Receptor Subtypes in DT40 Cells {#s3a}
-------------------------------------------------------------

Immunoblotting with IP~3~R subtype-selective antisera (Ab1-3) established that each of the stable DT40 cell lines specifically expressed only a single IP~3~R subtype ([Figure 2A](#pone-0054877-g002){ref-type="fig"}). An antiserum that recognizes a peptide sequence present in all mammalian IP~3~R subtypes (AbC) [@pone.0054877-Cardy1] was used to quantify relative levels of IP~3~R expression in the three cell lines ([Figure 2A](#pone-0054877-g002){ref-type="fig"}). The results demonstrate that, relative to IP~3~R3 (100%), levels of expression of IP~3~R1 and IP~3~R2 were 71±8% and 48±5%, respectively ([Figure 2A](#pone-0054877-g002){ref-type="fig"}). Because the density of IP~3~R may affect the sensitivity of intracellular Ca^2+^ stores to IP~3~ [@pone.0054877-Yamazaki1] and it is impracticable to generate cell lines expressing identical levels of each IP~3~R subtype, comparisons of the relative potencies of IP~3~ analogues for each IP~3~R subtype are expressed relative to the potency of (1,4,5)IP~3~ in the same cell line (see Methods).

![Functional expression of recombinant IP~3~ receptor subtypes in DT40 cells.\
(A) Western blots from DT40 cells stably expressing each of the IP~3~R subtypes. Each lane was loaded with lysate derived from ∼1.4×10^6^ cells stably expressing IP~3~R1, IP~3~R2 or IP~3~R3, or from DT40-KO cells (KO). The antisera used are selective for IP~3~R1-3 (Ab1-3) or they interact equally with all three IP~3~R subtypes (AbC) [@pone.0054877-Cardy1] (see Materials). An antiserum to β-actin was used to confirm the equivalent loading of lanes. Quantitative analysis of AbC immunoreactivity from 3 similar gels was used to establish expression levels of the three IP~3~R subtypes relative to IP~3~R3 (means ± SEM, n = 3) (lower panel). (B) A luminal Ca^2+^ indicator was used to record Ca^2+^ uptake into the intracellular stores of permeabilized DT40 cells expressing IP~3~R1 after addition of MgATP. Subsequent addition of (1,4,5)IP~3~ (at the concentrations shown) with thapsigargin (1 µM) allowed (1,4,5)IP~3~-evoked Ca^2+^ release to be quantified. The typical experiment shows traces averaged from 3 wells in a single plate. For clarity only a selection of the (1,4,5)IP~3~ concentrations are shown. The same methods were used to quantify the effects of all analogues. (C) Concentration-dependent effects of (1,4,5)IP~3~ on Ca^2+^ release from the intracellular stores of cells expressing IP~3~R1 (black), IP~3~R2 (blue) or IP~3~R3 (red). The same colour-codes are used in all subsequent figures. Results are means ± SEM from the number of independent experiments given in [Table 1](#pone-0054877-t001){ref-type="table"}. Here, and in many subsequent figures, some error bars are smaller than the symbols.](pone.0054877.g002){#pone-0054877-g002}

IP~3~-evoked Ca^2+^ Release by Subtypes of IP~3~ Receptor {#s3b}
---------------------------------------------------------

A low-affinity luminal Ca^2+^ indicator was used to report the free Ca^2+^ concentration within the endoplasmic reticulum of permeabilized DT40 cells ([Figure 2B](#pone-0054877-g002){ref-type="fig"}). IP~3~ failed to evoke Ca^2+^ release in DT40-KO cells, which lack IP~3~R (not shown) [@pone.0054877-Rahman1], but it was effective in DT40 cells stably expressing each of the three IP~3~R subtypes ([Figure 2B and C](#pone-0054877-g002){ref-type="fig"}) [@pone.0054877-Tovey1]. The results demonstrate that in each cell line, IP~3~ caused a concentration-dependent release of 60--75% of the intracellular Ca^2+^ stores, with Hill coefficients (h) of about 1, and pEC~50~ values of 7.06±0.05, 6.84±0.06 and 6.38±0.05 for IP~3~R1, IP~3~R2 and IP~3~R3, respectively ([Table 1](#pone-0054877-t001){ref-type="table"} and [Figure 2C](#pone-0054877-g002){ref-type="fig"}). Notwithstanding the moderate differences in IP~3~R expression in the different DT40 cell lines ([Figure 2A](#pone-0054877-g002){ref-type="fig"}), the relative sensitivities of IP~3~R1-3 to IP~3~ in these assays (IP~3~R1∼IP~3~R2\>IP~3~R3) are consistent with a general consensus that IP~3~R3 is the least sensitive of the IP~3~R subtypes [@pone.0054877-Iwai1].

10.1371/journal.pone.0054877.t001

###### Effects of IP~3~ analogues on Ca^2+^ release by subtypes of IP~3~ receptor.

![](pone.0054877.t001){#pone-0054877-t001-1}

                         IP~3~R1    IP~3~R2                     IP~3~R3                                                                                                                                                                                                                                                                                     
  --------------------- --------- ----------- -------------------------------------------- -------------------------------------- ---- ------- ----------- ----------- -------------------------------------- ---- ---------------------------------------- ----------- -------------------------------------------- -------------------------------------- ----
  (1,4,5)IP~3~             87      7.06±0.05                   0.99±0.05                                    75±1                   31    145    6.84±0.06   1.26±0.09                   61±2                   34                    417                     6.38±0.05                   1.26±0.07                                    64±2                   30
  (4,5)IP~2~              8128     5.09±0.12                   1.11±0.15                                    69±4                   4    6310    5.20±0.20   1.67±0.27                   56±4                   5                    11482                    4.94±0.07   1.28±0.03[\*](#nt104){ref-type="table-fn"}                   83±2                   3
  (1,3,4,5)IP~4~          11749    4.93±0.05                   1.09±0.16                                    66±6                   3    5495    5.26±0.09   2.26±0.18                   61±5                   3    114815[b](#nt103){ref-type="table-fn"}   3.94±0.03                   1.08±0.22                    36±1[a](#nt102){ref-type="table-fn"}   3
  2-deoxy(1,4,5)IP~3~      123     6.91±0.15                   0.84±0.07                                    82±3                   4     115    6.94±0.11   1.71±0.37                   65±2                   6                     324                     6.49±0.02                   1.36±0.10                                    74±3                   3
  (1,4,6)IP~3~            4365     5.36±0.19                   0.98±0.10                                    81±4                   6    12589   4.90±0.16   1.06±0.17                   68±2                   6                    15849                    4.80±0.12   2.58±0.61[\*](#nt104){ref-type="table-fn"}                   46±1                   6
  3-deoxy(1,4,5)IP~3~     3311     5.48±0.09   1.75±0.24[\*](#nt104){ref-type="table-fn"}                   61±2                   6    5888    5.23±0.07   1.78±0.34                   57±6                   6                    15849                    4.80±0.13                   2.59±0.68                                    53±7                   6
  MG(1,4,5)IP~3~           447     6.35±0.12                   0.95±0.10                                    73±4                   9     708    6.15±0.09   1.04±0.08                   57±3                   9                     1738                    5.76±0.11                   1.18±0.11                                    64±4                   8
  (1,3,4)IP~3~             ND         ND                           ND                       39±8[a](#nt102){ref-type="table-fn"}   3     ND        ND          ND       18±6[a](#nt102){ref-type="table-fn"}   3                      ND                        ND                           ND                       2±1[a](#nt102){ref-type="table-fn"}    3

The EC~50~, pEC~50~, Hill coefficient (h) and fraction of the intracellular Ca^2+^ stores released by a maximally effective concentration of each analogue are shown for each IP~3~R subtype. All results (except EC~50~) are shown as means ± SEM from n independent experiments. The (1,3,4,5)IP~4~ was provided by Calbiochem. ND, not determined.

Ca^2+^ release evoked with 100 µM of the analogue (where the highest attainable concentrations of ligand failed to saturate the response).

EC~50~ estimated by assuming that maximally effective concentrations of (1,3,4,5)IP~4~ and (1,4,5)IP~3~ release the same fraction of the Ca^2+^ stores.

Denotes Hill slopes that are significantly different (*P*\<0.05) from 1. Statistical comparisons of maximal Ca^2+^ release and pEC~50~ values used paired comparisons (Δmax or ΔpEC~50~), which are presented in [Table 2](#pone-0054877-t002){ref-type="table"}.

Interactions of IP~3~ Metabolites with IP~3~ Receptor Subtypes {#s3c}
--------------------------------------------------------------

Inositol 1,3,4,5-tetrakisphosphate ((1,3,4,5)IP~4~) is the immediate product of (1,4,5)IP~3~ phosphorylation by IP~3~ 3-kinase [@pone.0054877-Irvine1] ([Figure 3A](#pone-0054877-g003){ref-type="fig"}). Although (1,3,4,5)IP~4~ stimulated Ca^2+^ release via each of the three IP~3~R subtypes ([Figure 3B](#pone-0054877-g003){ref-type="fig"}), it was ∼100-fold less potent than IP~3~. Indeed in DT40-IP~3~R3 cells, which are the least sensitive to IP~3~ ([Figure 2C](#pone-0054877-g002){ref-type="fig"}), even 100 µM (1,3,4,5)IP~4~ failed to release the entire IP~3~-sensitive Ca^2+^ store ([Figures 3B and C](#pone-0054877-g003){ref-type="fig"}, and [Table 1](#pone-0054877-t001){ref-type="table"}). The purity of (1,3,4,5)IP~4~ supplied by Calbiochem is only ∼98%. We were therefore concerned that its effects on Ca^2+^ release might be mediated by contaminating (1,4,5)IP~3~. However, similar experiments using DT40-IP~3~R1 cells and synthetic (1,3,4,5)IP~4~, where the synthesis provides no opportunity for contamination by (1,4,5)IP~3~ [@pone.0054877-Riley1], established that the two sources of (1,3,4,5)IP~4~ were equipotent. Relative to (1,4,5)IP~3~, ΔpEC~50~ values were 2.09±0.07 and 1.97±0.04 (n = 3) for commercial and synthetic (1,3,4,5)IP~4~, respectively. Synthetic (1,3,4,5)IP~4~ (100 µM) had no significant effect on the Ca^2+^ content of the intracellular stores of permeabilized DT40 cells lacking IP~3~R (DT40-KO cells) (not shown). We conclude that (1,3,4,5)IP~4~ itself stimulates Ca^2+^ release via all IP~3~R, but only at concentrations ∼100-fold higher than with (1,4,5)IP~3~ ([Figures 3B and C](#pone-0054877-g003){ref-type="fig"}). The much reduced potency of (1,3,4,5)IP~4~ is consistent with loss of the 3-hydroxyl group reducing potency ([Table 1](#pone-0054877-t001){ref-type="table"} and see below) and with docking analyses, which suggest that although the 3-phosphate can be accommodated, the orientations of the phosphate groups are slightly distorted relative to (1,4,5)IP~3~ bound to the IBC ([Figure 3F](#pone-0054877-g003){ref-type="fig"}).

![(1,3,4,5)IP~4~ is a low-affinity full agonist of IP~3~ receptors.\
(A) (1,4,5)IP~3~ can be dephosphorylated to (1,4)IP~2~ or phosphorylated to (1,3,4,5)IP~4~, which can then be dephosphorylated to (1,3,4)IP~3~. (B) Effects of (1,3,4,5)IP~4~ (Calbiochem) on Ca^2+^ release via each of the three IP~3~R subtypes. (C) Paired comparisons of the effects of (1,4,5)IP~3~ and (1,3,4,5)IP~4~ are shown for each IP~3~R subtype. (D) Typical results from DT40-IP~3~R1 cells stimulated with (1,4,5)IP~3~ alone (black trace) or in the presence of (1,3,4,5)IP~4~ (5 µM, added 35 s before IP~3~; red trace). (E) Summary results show the effect of (1,3,4,5)IP~4~ on the concentration-dependent effects of (1,4,5)IP~3~ on Ca^2+^ release. Results (B, C and E) are means ± SEM from the number of independent experiments given in [Table 1](#pone-0054877-t001){ref-type="table"}. (F) (1,3,4,5)IP~4~ docked into the IBC of IP~3~R1 adopts a conformation in which the underlying (1,4,5)IP~3~ scaffold is only slightly distorted from that of (1,4,5)IP~3~ within the crystal structure of the IBC (right panel) [@pone.0054877-Bosanac1]. Docking of the NT into a 3D reconstruction of the entire IP~3~R1 [@pone.0054877-Ludtke1] has suggested a likely arrangement of the NT within the tetrameric IP~3~R [@pone.0054877-Seo1] (left panel). Within this proposed arrangement, the IBC can still bind (1,3,4,5)IP~4~ without obvious steric clashes.](pone.0054877.g003){#pone-0054877-g003}

It has been suggested that (1,3,4,5)IP~4~ potentiates the Ca^2+^ release evoked by (2,4,5)IP~3~ at IP~3~R1 [@pone.0054877-LoomisHusselbee1], although in other cells there was no evidence for this interaction [@pone.0054877-Bird1]. We re-examined this phenomenon by first adding (1,3,4,5)IP~4~ to permeabilized DT40-IP~3~R1 cells at a concentration (5 µM) near its threshold for evoking Ca^2+^ release, and then assessed subsequent responses to (1,4,5)IP~3~ ([Figure 3D](#pone-0054877-g003){ref-type="fig"}). The results, which show that (1,3,4,5)IP~4~ has no effect on the response to any concentration of (1,4,5)IP~3~ ([Figure 3E](#pone-0054877-g003){ref-type="fig"}), provide no support for the suggestion that (1,3,4,5)IP~4~ potentiates IP~3~-evoked Ca^2+^ release [@pone.0054877-LoomisHusselbee1]. Furthermore, the lack of inhibition of IP~3~-evoked Ca^2+^ release by (1,3,4,5)IP~4~ demonstrates that it is not a partial agonist of IP~3~R. We conclude that (1,3,4,5)IP~4~ is a low-affinity full agonist of all three IP~3~R subtypes.

Dephosphorylation of (1,3,4,5)IP~4~ by IP~3~ 5-phosphatase produces (1,3,4)IP~3~ ([Figure 3A](#pone-0054877-g003){ref-type="fig"}), which can accumulate to concentrations considerably exceeding that of (1,4,5)IP~3~ during sustained stimulation [@pone.0054877-Burgess1]. (1,3,4)IP~3~, even at a concentration of 100 µM, failed to stimulate release of the entire (1,4,5)IP~3~-sensitive Ca^2+^ store in any of the three cell lines ([Table 1](#pone-0054877-t001){ref-type="table"}). (1,3,4)IP~3~ is, therefore, at least 1000-fold less potent than (1,4,5)IP~3~. Comparing the fraction of the Ca^2+^ stores released by 100 µM (1,3,4)IP~3~ in cells expressing each of the three IP~3~R subtypes indicates that the response was greatest in DT40-IP~3~R1 cells and smallest in DT40-IP~3~R3 cells ([Table 1](#pone-0054877-t001){ref-type="table"}). The effects of (1,3,4)IP~3~ on the three IP~3~R subtypes (IP~3~R1\> IP~3~R2\>\> IP~3~R3) therefore match the rank order of potency of (1,4,5)IP~3~ ([Table 1](#pone-0054877-t001){ref-type="table"}), consistent perhaps with minor contamination (\<0.1%) of the (1,3,4)IP~3~ with (1,4,5)IP~3~ or (1,3,6)IP~3~ accounting for the activity. These results suggest that (1,3,4)IP~3~ is itself unlikely to bind to IP~3~R. This is consistent with a requirement for a vicinal 4,5-bisphosphate structure in all known inositol phosphate ligands of IP~3~R [@pone.0054877-Wilcox1]. It is impossible for us to verify this independently by equilibrium competition ^3^H-IP~3~ binding because DT40 cells are the only homogenous source of IP~3~R subtypes presently available to us, but the low density of IP~3~Rs would require impracticably large numbers of cells for binding studies.

Type 3 IP~3~ Receptors are Slightly Less Sensitive to Loss of the 1-phosphate from (1,4,5)IP~3~ {#s3d}
-----------------------------------------------------------------------------------------------

Removal of the 1-phosphate from (1,4,5)IP~3~ to give (4,5)IP~2~ caused a similar ∼83-fold decrease in potency for IP~3~R1 and IP~3~R2 ([Figures 4A and B](#pone-0054877-g004){ref-type="fig"}, [Tables 1](#pone-0054877-t001){ref-type="table"} and [2](#pone-0054877-t002){ref-type="table"}). Contamination of (4,5)IP~2~ with (1,4,5)IP~3~ cannot explain this activity because (4,5)IP~2~ was prepared by total synthesis and purified by ion-exchange chromatography [@pone.0054877-Sureshan2]. This is consistent with previous functional analyses of native IP~3~R [@pone.0054877-Wilcox1] and with the ability of (4,5)IP~2~ to compete with ^3^H-(1,4,5)IP~3~ for binding to these IP~3~R subtypes heterologously expressed in Sf9 cells [@pone.0054877-Nerou1].

![IP~3~ receptor subtypes differ slightly in their requirements for a 1-phosphate group in (1,4,5)IP~3~.\
(A) Effects of (4,5)IP~2~ on Ca^2+^ release via each IP~3~R subtype. (B) Paired comparisons of the effects of (1,4,5)IP~3~ and (4,5)IP~2~ are shown for each IP~3~R subtype. (C) The 1-phosphate group of (1,4,5)IP~3~ interacts directly with R568 and via water (blue sphere) with K569 within the α-domain of the IBC [@pone.0054877-Bosanac1]. The primary sequences of this region (residues 561-580) are similar for each IP~3~R subtype. (D) Structural homology models of the NT of mouse IP~3~R2 and rat IP~3~R3 were built using structures of the SD (Protein Data Bank: 1XZZ) and IBC (Protein Data Bank: 1N4K) from IP~3~R1 and these were then aligned using the published structure of the NT of rat IP~3~R1 (Protein Data Bank: 3UJ0).](pone.0054877.g004){#pone-0054877-g004}

10.1371/journal.pone.0054877.t002

###### Relative potencies of IP~3~ analogues at different IP~3~ receptor subtypes.

![](pone.0054877.t002){#pone-0054877-t002-2}

                                                      IP~3~R1                   IP~3~R2                  IP~3~R3                                                                                                                                                  
  ------------------------------------------------- ----------- --------------------------------------- --------- ----------- --------------------------------------- ------ -------------------------------------------- --------------------------------------- ------
  (4,5)IP~2~                                         1.92±0.15                   13±5                     81±3     1.92±0.05                    8±3                    65±4   1.38±0.06[\*](#nt107){ref-type="table-fn"}                   −1±2                    77±4
  2-deoxy(1,4,5)IP~3~                                0.09±0.10                   −1±2                     81±3     0.19±0.14                   −3±3                    63±4                   −0.17±0.08                                    0±2                    77±4
  (1,4,6)IP~3~                                       1.57±0.09                   −2±5                     76±5     1.67±0.15                   −3±6                    64±5                   1.45±0.09                                     8±6                    55±7
  3-deoxy(1,4,5)IP~3~                                1.61±0.12   21±2[\*](#nt107){ref-type="table-fn"}    80±4     1.64±0.21   12±4[\*](#nt107){ref-type="table-fn"}   68±3                   1.66±0.17                    20±5[\*](#nt107){ref-type="table-fn"}   66±3
  (1,3,4,5)IP~4~ [a](#nt106){ref-type="table-fn"}    2.09±0.07   17±5[a](#nt106){ref-type="table-fn"}     77±1     2.18±0.04   7±0[\*](#nt107){ref-type="table-fn"}    67±6                   2.38±0.07                     ND[a](#nt106){ref-type="table-fn"}     77±4
  MG(1,4,5)IP~3~                                     0.69±0.10                    4±5                     77±3     0.7±0.14    11±3[\*](#nt107){ref-type="table-fn"}   64±3                   0.64±0.15                                     4±4                    61±3

From paired comparisons with (1,4,5)IP~3~, the relative potency and differences in maximal Ca^2+^ release are shown for each analogue at each IP~3~R subtype. Results show means ± SEM, with n provided in [Table 1](#pone-0054877-t001){ref-type="table"}. To allow direct comparison with responses evoked by (1,4,5)IP~3~, maximal Ca^2+^ release evoked by (1,4,5)IP~3~ in experiments paired with the analogues are also shown ((1,4,5)IP~3~ max).

With (1,3,4,5)IP~4~ it was impossible to attain concentrations (\>100 µM) that evoked a maximal response for all IP~3~R subtypes; in these cases the maximal responses were not subject to statistical analysis. The relative potency of (1,3,4,5)IP~4~ at IP~3~R subtypes was estimated by assuming it was a full agonist that released the same fraction of the intracellular Ca^2+^ stores as a maximally effective concentration of (1,4,5)IP~3~ in parallel analyses. ND, not determined.

Denotes values significantly different (*P*\<0.05) from IP~3~R1 (for ΔpEC~50~ values) or from (1,4,5)IP~3~ in paired comparisons with the analogue (for Δmax values).

However, the difference in potency of (1,4,5)IP~3~ and (4,5)IP~2~ at IP~3~R3 was only ∼24-fold (ΔpEC~50~ = 1.38±0.06) ([Figure 4B](#pone-0054877-g004){ref-type="fig"}, [Table 2](#pone-0054877-t002){ref-type="table"}). Our results suggest that although removal of the 1-phosphate from (1,4,5)IP~3~ reduces potency at all IP~3~R subtypes, IP~3~R3 is least affected. Within the IBC of IP~3~R1, the 1-phosphate of (1,4,5)IP~3~ interacts directly with R568 and, via water, with K569 [@pone.0054877-Bosanac1] ([Figure 4C](#pone-0054877-g004){ref-type="fig"}). These residues and their immediate neighbours are conserved in IP~3~R2 and IP~3~R3 ([Figure 4C](#pone-0054877-g004){ref-type="fig"}). The only residues known to interact directly with (1,4,5)IP~3~ are within the IBC ([Figure 1A](#pone-0054877-g001){ref-type="fig"}) and primary sequences of the IBC are highly conserved between IP~3~R subtypes. It is therefore unsurprising that homology models based on the IBC of IP~3~R1 [@pone.0054877-Bosanac1] suggest almost indistinguishable structures for the IBCs from IP~3~R2 and IP~3~R3 ([Figure 4D](#pone-0054877-g004){ref-type="fig"}). Furthermore, the IBCs from the three IP~3~R subtypes have the same affinity for (1,4,5)IP~3~ [@pone.0054877-Iwai1]. However, both full-length IP~3~R and the NT from different IP~3~R subtypes differ in their affinities for (1,4,5)IP~3~. These observations demonstrate that interactions between the IBC and other parts of the IP~3~R, notably the suppressor domain (SD, residues 1--223), influence ligand binding [@pone.0054877-Rossi1], [@pone.0054877-Iwai1]. The complexity of these interactions between the IBC and other domains together with the need for only very modest conformational differences between subtypes to account for the small differences in ligand potency make it difficult to define the residues responsible for modulating the interactions between the IBC and the 1-phosphate group of (1,4,5)IP~3~ in IP~3~R3.

Removal of the 2- and 3-hydroxyl Groups from (1,4,5)IP~3~ or Inverting their Orientations Similarly Affect Interactions with all IP~3~ Receptor Subtypes {#s3e}
--------------------------------------------------------------------------------------------------------------------------------------------------------

The structure of (1,4,5)IP~3~ bound to the IBC of IP~3~R1 shows the 2-hydroxyl group of (1,4,5)IP~3~ exposed to solvent ([Figure 1A](#pone-0054877-g001){ref-type="fig"}) [@pone.0054877-Bosanac1] and previous structure-activity studies of native IP~3~R suggested that removal of the 2-hydroxyl moiety from (1,4,5)IP~3~ to give 2-deoxy(1,4,5)IP~3~ minimally affects activity [@pone.0054877-Rossi1], [@pone.0054877-Nerou1]. Our results confirm that observation for all three IP~3~R subtypes: 2-deoxy(1,4,5)IP~3~ and (1,4,5)IP~3~ are equipotent at all three IP~3~R subtypes ([Figures 5A and B](#pone-0054877-g005){ref-type="fig"}, [Tables 1](#pone-0054877-t001){ref-type="table"} and [2](#pone-0054877-t002){ref-type="table"}).

![The 2- and 3-hydroxy groups of (1,4,5)IP~3~ interact similarly with each IP~3~ receptor subtype.\
(A) Effects of 2-deoxy-(1,4,5)IP~3~ on Ca^2+^ release via each IP~3~R subtype. (B) Paired comparisons of the effects of (1,4,5)IP~3~ and 2-deoxy-(1,4,5)IP~3~ are shown for each IP~3~R subtype. (C and D) Similar analyses of 3-deoxy-(1,4,5)IP~3~. Results (A-D) are means ± SEM from the number of independent experiments given in [Table 1](#pone-0054877-t001){ref-type="table"}.](pone.0054877.g005){#pone-0054877-g005}

Removal of the 3-hydroxyl of (1,4,5)IP~3~ (3-deoxy(1,4,5)IP~3~) caused a ∼40-fold decrease in potency (ΔpEC~50~ ∼1.6) that was similar for all three IP~3~R subtypes ([Figures 5C and D](#pone-0054877-g005){ref-type="fig"}, [Tables 1](#pone-0054877-t001){ref-type="table"} and [2](#pone-0054877-t002){ref-type="table"}). This decrease is larger than that observed for either Ca^2+^ release from cells expressing largely IP~3~R1 (∼3-fold) [@pone.0054877-Kozikowski1] or for binding to heterologously expressed IP~3~R1-3 (7- 20-fold) [@pone.0054877-Nerou1].

(1,4,6)IP~3~ is an analogue of (1,4,5)IP~3~ in which the orientations of the 2- and 3-hydroxyl groups are inverted ([Figures 1B](#pone-0054877-g001){ref-type="fig"} and [6A](#pone-0054877-g006){ref-type="fig"}). (1,4,6)IP~3~ was less potent than (1,4,5)IP~3~ and the loss of potency was similar for all three IP~3~R subtypes ([Figures 6B and C](#pone-0054877-g006){ref-type="fig"}, [Tables 1](#pone-0054877-t001){ref-type="table"} and [2](#pone-0054877-t002){ref-type="table"}). The loss of potency probably results from inverting the 3-hydroxyl group from its equatorial position in (1,4,5)IP~3~ to an axial position in (1,4,6)IP~3~ ([Figure 6A](#pone-0054877-g006){ref-type="fig"}) because [l]{.smallcaps}-*scyllo*(1,2,4)IP~3~, which differs from (1,4,5)IP~3~ only in its inverted orientation of the 2-hydroxyl group, was reported to have the same affinity as (1,4,5)IP~3~ for all three IP~3~R subtypes [@pone.0054877-Nerou1].

![Interactions of (1,4,6)IP~3~ with IP~3~ receptor subtypes.\
(A) Structures of (1,4,5)IP~3~ and (1,4,6)IP~3~ drawn to show how they differ only in the relative orientations of the 2- and 3-hydroxyl groups of (1,4,5)IP~3~. (B) Effects of (1,4,6)IP~3~ on Ca^2+^ release via each IP~3~R subtype. (C) Paired comparisons of the effects of (1,4,5)IP~3~ and (1,4,6)IP~3~ are shown for each IP~3~R subtype. Results (B and C) are means ± SEM from the number of independent experiments given in [Table 1](#pone-0054877-t001){ref-type="table"}.](pone.0054877.g006){#pone-0054877-g006}

MG-(1,4,5)IP~3~ is a Full Agonist of IP~3~ Receptors with Slightly Lesser Affinity than (1,4,5)IP~3~ {#s3f}
----------------------------------------------------------------------------------------------------

MG(1,4,5)IP~3~ in which 4-carboxy-malachite green is attached via an aminopropyl linkage to the 1-phosphate of (1,4,5)IP~3~ ([Figure 1B](#pone-0054877-g001){ref-type="fig"}) was originally synthesized to explore its potential as a ligand of IP~3~R that might allow chromophore-assisted laser inactivation (CALI) of IP~3~R [@pone.0054877-Inoue1], [@pone.0054877-Inoue2]. The first study, using surface plasmon resonance to assess binding to an N-terminal fragment of IP~3~R1 (residues 1--885), surprisingly suggested that MG(1,4,5)IP~3~ had ∼170-fold greater affinity than (1,4,5)IP~3~, whereas fluorescein similarly attached to the 1-position of (1,4,5)IP~3~ had no significant effect on affinity [@pone.0054877-Inoue1]. The results were important because they suggested that MG(1,4,5)IP~3~ might be the ligand with the highest known affinity for IP~3~R, and they were unexpected because disrupting interaction of the 1-phosphate group of (1,4,5)IP~3~ with the IP~3~R would be expected to reduce affinity ([Figure 4](#pone-0054877-g004){ref-type="fig"} and [Table 1](#pone-0054877-t001){ref-type="table"}) [@pone.0054877-Wilcox1]. A subsequent study of Ca^2+^ release from permeabilized smooth muscle cells concluded that the EC~50~ for MG(1,4,5)IP~3~ was ∼7-fold higher than that for (1,4,5)IP~3~ [@pone.0054877-Inoue1]. The disparity between the reported very high affinity of MG(1,4,5)IP~3~ for the N-terminal of IP~3~R1 and its modest potency in functional assays of smooth muscle has not been explained. We considered two possibilities. MG(1,4,5)IP~3~ may be a high-affinity partial agonist or it may differ massively in its affinity for IP~3~R1 and the endogenous IP~3~R of smooth muscle.

Our results indicate that MG(1,4,5)IP~3~ is ∼5-fold less potent than (1,4,5)IP~3~ at each IP~3~R subtype ([Figures 7A and B](#pone-0054877-g007){ref-type="fig"}, [Tables 1](#pone-0054877-t001){ref-type="table"} and [2](#pone-0054877-t002){ref-type="table"}). This is consistent with functional assays of smooth muscle [@pone.0054877-Inoue1] and with our results from native IP~3~R (largely IP~3~R2) in rat hepatocytes, where ΔpEC~50~ was 0.57±0.03 for (1,4,5)IP~3~ (pEC~50~ = 6.81±0.02) and MG(1,4,5)IP~3~ (pEC~50~ = 6.24±0.01) (Taylor CW, unpublished data). These results establish that MG(1,4,5)IP~3~ interacts similarly with all three IP~3~R subtypes and that it is less potent than (1,4,5)IP~3~. In aqueous solution, the triphenylmethane component of MG(1,4,5)IP~3~ exists as a mixture of several inter-converting species, whose relative proportions are sensitive to pH [@pone.0054877-Hagiwara1]. At pH 7.4, a colourless triphenylmethanol form with a tetrahedral structure is likely to co-exist with the coloured propeller-shaped form shown in [Figures 1B](#pone-0054877-g001){ref-type="fig"} and [7F](#pone-0054877-g007){ref-type="fig"}. Because the earlier surface plasma resonance experiments [@pone.0054877-Inoue1], [@pone.0054877-Inoue2] and our analyses were performed at similar pH, we assume that the proportions of the two forms were similar in each analysis.

![MG(1,4,5)-IP~3~ is a full agonist of all IP~3~ receptor subtypes.\
(A) Effects of MG(1,4,5)IP~3~ on Ca^2+^ release via each IP~3~R subtype. (B) Paired comparisons of the effects of (1,4,5)IP~3~ and MG(1,4,5)IP~3~ are shown for each IP~3~R subtype. Results (A and B) are means ± S.E.M. from the number of independent experiments given in [Table 1](#pone-0054877-t001){ref-type="table"}. (C) Equilibrium-competition binding of ^3^H-IP~3~ (1.5 nM) to cerebellar membranes in CLM containing 220 nM free \[Ca^2+^\] in the presence of the indicated concentrations of (1,4,5)IP~3~ or MG(1,4,5)IP~3~. (D) Typical results showing effects of MG(1,4,5)IP~3~ (30 nM, added 35 s before (1,4,5)IP~3~) on Ca^2+^ release from DT40-IP~3~R cells. (E) Summary results (means ± SEM from 3 independent experiments) show concentration-dependent effects of (1,4,5)IP~3~ alone or in the presence of MG(1,4,5)IP~3~ (300 nM). (F) MG(1,4,5)IP~3~ docked into the IBC of IP~3~R1 (top; (1,4,5)IP~3~ shown in gray) shows that it can be accommodated within the likely structure of the tetrameric IP~3~R without steric clashes (bottom).](pone.0054877.g007){#pone-0054877-g007}

In equilibrium-competition binding assays in CLM using cerebellar membranes, which predominantly express IP~3~R1 [@pone.0054877-Taylor2], (1,4,5)IP~3~ bound with an affinity that was ∼7-fold greater than that of MG(1,4,5)IP~3~ (ΔpK~D~ = 0.86±0.08, n = 3): pK~D~ = 8.29±0.03 and 7.43±0.08, for (1,4,5)IP~3~ and MG(1,4,5)IP~3~, respectively ([Figure 7C](#pone-0054877-g007){ref-type="fig"} and [Table 3](#pone-0054877-t003){ref-type="table"}). The ∼7-fold lesser affinity of MG(1,4,5)IP~3~ for IP~3~R1 relative to (1,4,5)IP~3~ and its similarly reduced potency (∼5-fold, [Table 2](#pone-0054877-t002){ref-type="table"}) are consistent with the large malachite green structure perturbing interaction of the 1-phosphate of (1,4,5)IP~3~ with the IBC, and they suggest that MG(1,4,5)IP~3~ is a full agonist of IP~3~R. The latter conclusion is further substantiated by the results shown in [Figures 7D and E](#pone-0054877-g007){ref-type="fig"}. These show that the Ca^2+^ release evoked by (1,4,5)IP~3~ is unaffected by the presence of 300 nM MG(1,4,5)IP~3~, which itself released 34±4% of the Ca^2+^ stores. The pEC~50~ was 7.41±0.09 and 7.01±0.37 (n = 3) for (1,4,5)IP~3~ alone and in the presence of MG(1,4,5)IP~3~, respectively ([Figure 7E](#pone-0054877-g007){ref-type="fig"}). A weak partial agonist, by contrast, would be expected, at concentrations sufficient to evoke a response, to occupy enough IP~3~R to shift the concentration-dependence of the response to (1,4,5)IP~3~ to higher concentrations [@pone.0054877-Rossi1]. These results establish that MG(1,4,5)IP~3~ is not a partial agonist of IP~3~R1. We conclude that MG(1,4,5)IP~3~ is a full agonist of IP~3~R with an affinity that is ∼7-fold less than that of (1,4,5)IP~3~.

10.1371/journal.pone.0054877.t003

###### Interactions of MG(1,4,5)IP~3~ with type 1 IP~3~ receptors.

![](pone.0054877.t003){#pone-0054877-t003-3}

                    DT40-IP~3~R1 cells   Cerebellum                            
  ---------------- -------------------- ------------ ------ ------ ----------- -----------
  (1,4,5)IP~3~              91            7.04±0.1    77±2   5.13   8.29±0.03   1.25±0.29
  MG(1,4,5)IP~3~           447           6.35±0.12    73±4   37.2   7.43±0.08   1.08±0.35

Results from functional assays of Ca^2+^ release from DT40-IP~3~R1 cells ([Figure 7B](#pone-0054877-g007){ref-type="fig"}) and of equilibrium competition binding to cerebellar membranes ([Figure 7C](#pone-0054877-g007){ref-type="fig"}) compare the pEC~50~ and pK~D~ values for (1,4,5)IP~3~ and MG(1,4,5)IP~3~. Results (except EC~50~ and K~D~) show means ± SEM from 3--9 independent experiments. The final column shows pK~D~-pEC~50~ for each ligand.

Discussion {#s4}
==========

The primary sequence of the IBC, which is responsible for recognition of (1,4,5)IP~3~ by IP~3~R, is well conserved between IP~3~R subtypes, and in isolation the IBC from each IP~3~R subtype binds IP~3~ with similar affinity [@pone.0054877-Iwai1]. Although there are high-resolution structures of this region for only IP~3~R1 [@pone.0054877-Bosanac1], [@pone.0054877-Seo1], [@pone.0054877-Bosanac2], [@pone.0054877-Lin1], homology modelling suggests that the IBC structures of the three IP~3~R subtypes are very similar ([Figure 4D](#pone-0054877-g004){ref-type="fig"}). It is, therefore, unsurprising that structure-activity relationships for the three IP~3~R subtypes, most derived from comparisons of cells expressing mixtures of IP~3~R subtypes, are similar [@pone.0054877-Wilcox1], [@pone.0054877-DeLisle1], [@pone.0054877-Lu1]. Nevertheless, residues outside the IBC, notably the SD ([Figure 1A](#pone-0054877-g001){ref-type="fig"}), reduce the affinity of the IBC to differing extents for different IP~3~R subtypes [@pone.0054877-Iwai1]. Such differences and the minor differences in the primary sequence of the IBC between IP~3~R subtypes leave open the possibility that it may be possible to develop subtype-selective ligands of IP~3~R. Hitherto, the only systematic comparison of the ligand recognition properties of homogenous populations of IP~3~R subtypes examined only ligand binding to mammalian IP~3~R expressed in insect Sf9 cells [@pone.0054877-Nerou1]. We have now extended the analysis to functional assays of mammalian IP~3~R expressed in a null background, namely DT40 cells in which the genes for all endogenous IP~3~R have been disrupted [@pone.0054877-Sugawara1] ([Figure 2](#pone-0054877-g002){ref-type="fig"}).

All high-affinity inositol phosphate agonists of IP~3~R have structures equivalent to the 4,5-bisphosphate and 6-hydroxyl groups of (1,4,5)IP~3~ [@pone.0054877-Potter1], [@pone.0054877-Wilcox1], [@pone.0054877-Nerou1], and with the exception of (1,3,4)IP~3~ (which was effectively inactive), all ligands examined herein retain these groups ([Figure 1B](#pone-0054877-g001){ref-type="fig"}). Most of the ligands examined were either inactive ((1,3,4)IP~3~) or their potency relative to (1,4,5)IP~3~ suggested a lack of selectivity for IP~3~R subtypes (MG(1,4,5)IP~3~, (1,4,6)IP~3~, (1,3,4,5)IP~4~, 2-deoxy(1,4,5)IP~3~ and 3-deoxy(1,4,5)IP~3~) ([Figures 3](#pone-0054877-g003){ref-type="fig"}, [5](#pone-0054877-g005){ref-type="fig"}, [6](#pone-0054877-g006){ref-type="fig"} and [7](#pone-0054877-g007){ref-type="fig"}, [Tables 1](#pone-0054877-t001){ref-type="table"} and [2](#pone-0054877-t002){ref-type="table"}). The potencies of each of these agonists for each IP~3~R subtype are consistent with known structure-activity relationships [@pone.0054877-Wilcox1], [@pone.0054877-Nerou1] and with the structure of (1,4,5)IP~3~ bound to the IBC [@pone.0054877-Bosanac1] ([Figure 1A](#pone-0054877-g001){ref-type="fig"}). Loss of the 2-hydroxyl minimally affects activity, loss of either the 3-hydroxyl or 1-phosphate or inverting the orientation of the 3-hydroxyl causes the potency to decrease substantially, and addition of malachite green to the 1-phosphate of (1,4,5)IP~3~ causes a modest (∼7-fold) decrease in potency ([Tables 1](#pone-0054877-t001){ref-type="table"} and [2](#pone-0054877-t002){ref-type="table"}). We conclude that the structure-activity relationships for all three mammalian IP~3~R are broadly similar.

MG(1,4,5)IP~3~ was reported to bind with unexpectedly high affinity to an N-terminal fragment of IP~3~R1 [@pone.0054877-Inoue1], but our results, in line with subsequent analyses of smooth muscle cells from the same group [@pone.0054877-Inoue1], suggest that MG(1,4,5)IP~3~ interacts similarly with all IP~3~R subtypes and that it is a full agonist with an affinity that is ∼7-fold lower than that of (1,4,5)IP~3~ ([Figure 7](#pone-0054877-g007){ref-type="fig"} and [Tables 2](#pone-0054877-t002){ref-type="table"} and [3](#pone-0054877-t003){ref-type="table"}). This is consistent with evidence suggesting that even substantial additions to the 1-phosphate of (1,4,5)IP~3~ (eg, fluorescein and 3-aminopropyl) are well-tolerated [@pone.0054877-Inoue1], [@pone.0054877-Inoue2], [@pone.0054877-Nakanishi1]. It is also consistent with our docking studies, which suggest that even these very large additions to the 1-phosphate moiety of (1,4,5)IP~3~ do not create steric clashes within the tetrameric IP~3~R ([Figure 7F](#pone-0054877-g007){ref-type="fig"}).

The necessity of the 4,5-bisphosphate and 6-hydroxyl moieties [@pone.0054877-Wilcox2], and the considerable loss of affinity associated with modifying the 3-hydroxyl group of (1,4,5)IP~3~ ([Figures 3C, D](#pone-0054877-g003){ref-type="fig"} and [5C, D](#pone-0054877-g005){ref-type="fig"}) restrict opportunities to tag (1,4,5)IP~3~ to modifications of the 1- and 2-positions. Our previous work has shown that modification of the 2-position is compatible with high-affinity binding to IP~3~R, but it reduces efficacy [@pone.0054877-Rossi1], [@pone.0054877-Marchant2]. Our demonstration that MG(1,4,5)IP~3~ is a high-affinity full agonist of IP~3~R ([Figure 7](#pone-0054877-g007){ref-type="fig"}) therefore identifies an opportunity to develop fluorescent, or otherwise modified, ligands of IP~3~R that might be expected to come close to mimicking (1,4,5)IP~3~ in their interactions with IP~3~R.

Only one synthetic ligand discriminated modestly between IP~3~R subtypes. (4,5)IP~2~ lacks the 1-phosphate group of the endogenous ligand, (1,4,5)IP~3~ ([Figure 1B](#pone-0054877-g001){ref-type="fig"}). In keeping with considerable published evidence [@pone.0054877-Wilcox1], [@pone.0054877-Nerou1], this causes a substantial decrease in potency at all IP~3~R subtypes ([Figure 4](#pone-0054877-g004){ref-type="fig"}, [Tables 1](#pone-0054877-t001){ref-type="table"} and [2](#pone-0054877-t002){ref-type="table"}). The loss of potency is, however, significantly less pronounced (∼24-fold) for IP~3~R3 than for the other IP~3~R subtypes (∼80-fold) ([Table 2](#pone-0054877-t002){ref-type="table"}). The difference is unlikely to be due to residues with the IBC itself because the IBCs of all three IP~3~R subtypes bind (1,4,5)IP~3~ with indistinguishable affinity [@pone.0054877-Iwai1] and the residues that interact with the 1-phosphate group are conserved between IP~3~R ([Figure 4C](#pone-0054877-g004){ref-type="fig"}). We instead suggest that subtype-selective interactions of the IBC with other domains, perhaps the SD, subtly modify interaction of the 1-phosphate group of (1,4,5)IP~3~ with two basic residues within the IBC ([Figure 4C](#pone-0054877-g004){ref-type="fig"}).

Using homogenous populations of mammalian IP~3~R and a variety of (1,4,5)IP~3~ analogues, we have shown that the three IP~3~R subtypes have very similar ligand recognition properties. However, the decrease in affinity caused by loss of the 1-phosphate group is less for IP~3~R3. Finally, we have shown that MG(1,4,5)IP~3~ is a full agonist of IP~3~R with only modestly reduced affinity, suggesting that attachment of fluorescent tags to the 1-phosphate of (1,4,5)IP~3~ [@pone.0054877-Lampe1] is a feasible strategy for producing modified analogues of (1,4,5)IP~3~ that closely mimic the native messenger.
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